<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04081402</url>
  </required_header>
  <id_info>
    <org_study_id>HU-014_P1/3_CFL</org_study_id>
    <nct_id>NCT04081402</nct_id>
  </id_info>
  <brief_title>A Phase 1/3 Clinical Trial to Evaluate the Safety and Efficacy of HUTOX Compared to Botox® in Subjects With Moderate to Severe Crow's Feet Lines</brief_title>
  <official_title>A Phase 1/3 Clinical Trial to Evaluate the Safety and Efficacy of HUTOX Compared to Botox® in Subjects With Moderate to Severe Crow's Feet Lines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huons Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huons Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1/3 Clinical Trial to Evaluate the Safety and Efficacy of HUTOX Compared to Botox® in
      Subjects With Moderate to Severe Crow's Feet Lines
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline of Crow's feet Lines improvement rate [Time Frame: Week 4]</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">290</enrollment>
  <condition>Crow's Feet Lines</condition>
  <arm_group>
    <arm_group_label>HU-014 Inj</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Botox Inj</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HU-014</intervention_name>
    <description>Hutox Inj(Clostridium botulinum type A)</description>
    <arm_group_label>HU-014 Inj</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Botox Inj</intervention_name>
    <description>Botox Inj(Clostridium botulinum type A)</description>
    <arm_group_label>Botox Inj</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Bilaterally symmetrical moderate-to-severe CFL at maximum smile on the FWS as rated by
             the investigator

        Exclusion Criteria:

          -  Volunteer who has history of any diseases following. (myasthenia gravis, Eaton-Lambert
             syndrome, amyotrophic lateral sclerosis etc.)

          -  From screening, Subject who get a plastic Surgery within 48 Weeks

          -  Subject who has skin disorder including infection and scar on injection site

          -  Subject who takes a medication including skeletal muscle relaxants, Aminoglycoside,
             lincomycin, anticholinergic drug, benzodiazepine, benzamide etc.

          -  Subject who takes a medication including anticoagulant, antithrombotic drug except low
             dose aspirin (below 325 mg/day)

          -  Any condition that, in the view of the investigator, would interfere with study
             participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jungmin Yu, Researcher</last_name>
    <phone>070-7492-5100</phone>
    <email>jungmin-yu@huons.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yubeen Choi, Researcher</last_name>
    <phone>070-7492-5965</phone>
    <email>ybin9398@huons.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Huons</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huon</last_name>
      <phone>07074925149</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 5, 2019</study_first_submitted>
  <study_first_submitted_qc>September 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2019</study_first_posted>
  <last_update_submitted>September 5, 2019</last_update_submitted>
  <last_update_submitted_qc>September 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

